An expert outlines a practical framework for diagnosis, treatment initiation, and dose optimization in children with growth hormone deficiency.

An expert reviews key considerations for IGF-1 monitoring, timing of blood draws, and dose individualization when transitioning patients from daily growth hormone to long-acting analogs.

An expert compares insights from historical and contemporary growth hormone registries with randomized trial data, highlighting their complementary roles in evaluating long-acting GH analogs.

An expert discusses how clinicians can apply registry data alongside randomized trial evidence to address long-term safety, persistence, and real-world outcomes in growth hormone therapy.

An expert explains why long-acting growth hormone analogs represent more than a convenience upgrade, emphasizing adherence, treatment burden, and future directions in individualized dosing.